Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07480356 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
A Phase 3 study, sponsored by Protara Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 284
- Enrollment target
NCT07480356 is a Phase 3 study that is actively recruiting participants, run by Protara Therapeutics. The registered enrollment target is 284 participants.
The verdict
NCT07480356, a Phase 3 study, is actively recruiting participants, sponsored by Protara Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 284 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or older. The main questions it aims to answer are: * Can the study drug help participants with this type of cancer? * Is the study drug safe? * What are the side effects of the study drug? Researchers will compare TARA-002 to chemotherapy to see if TARA-002 works to treat NMIBC.
Interventions
- DRUG TARA-002
- DRUG Investigator's Choice of Intravesical Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2026-05-29 |
| Est. Completion | 2032-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07480356
The ClinicalTrials.gov registry entry for NCT07480356 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 284 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protara Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TARA-002 is the first listed.
NCT07480356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07480356 about?
NCT07480356 is a clinical study titled "Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer". The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or older. The main questions it aims to answer are: * Can the study drug help participants with this type of cancer? * Is the study drug safe?...
What is the current status of trial NCT07480356?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 284 participants. The study started on 2026-05-29. Estimated completion is 2032-11.
What interventions are being tested in trial NCT07480356?
The interventions under investigation include: TARA-002 (DRUG), Investigator's Choice of Intravesical Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT07480356?
This trial is sponsored by Protara Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.